↓ Skip to Main Content
Thasso
Thasso the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Log in

Main Navigation

  • english
    • english
    • français
    • deutsch
    • italiano
    • español
    • português
  • thasso
  • thasso post
  • thasso toolbox
    • theragenomics: useful links
    • theragenomics: biomarkers
    • theragenomics: companion tests
    • theragenomics: drug labels with annotated information
    • theragenomics: drugs and genes
    • theragenomics: the world of alleles
    • theragenomics: allele-related guideline information
    • drug interactions
    • drug information
    • drug adverse reactions
    • drugs: risk evaluation and mitigation strategies (REMS)
    • theragenomics: videos
  • thasso academy
    • health authorities
    • patient & consumer health
    • public domain
      • Swiss Academy of Medical Sciences
      • EUPATI The European Patients’ Academy on Therapeutic Innovation
    • companies
    • products
    • about
  • thasso community
    • thasso: simple chat
    • thasso: video chat
    • theragenomics: survey at thasso
      • survey participants
    • forum
      • patient groups / subgroups
      • group
      • lounge
      • events
      • gallery
  • thasso: about
    • vision
    • background
    • the apomediary patient
    • contact
    • disclaimers
    • policies
  • donations
    • thasso – thank you
    • Donation Confirmation

Tag: T790M Mutation

Theragenomic medicine: FDA approves Osimertinib (Tagrisso) to treat patients with non-small cell lung cancer (NSCLC) who carry the EGFR mutation T790M

By Joseph Gut - thasso Posted on November 14, 2015 Posted in Genetic Predisposition, New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine Tagged with American Food & Drug Administration (FDA), EGFR, EGFR Mutation, Epidermal Growth Factor Receptor (EGFR), Non-Small Cell Lung Cancer (NSCLC), T790M Mutation, Thasso Post, Theragenomic Medicine
Theragenomic medicine: FDA approves Osimertinib (Tagrisso) to treat patients with non-small cell lung cancer (NSCLC) who carry the EGFR mutation T790M

November 14, 2015 – The American Food and Drug Administration (FDA) just granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso) was approved for patients whose tumors have a specific …

Theragenomic medicine: FDA approves Osimertinib (Tagrisso) to treat patients with non-small cell lung cancer (NSCLC) who carry the EGFR mutation T790M Read more »

Footer Menu

  • english
  • thasso
  • thasso post
  • thasso toolbox
  • thasso academy
  • thasso community
  • thasso: about
  • donations
Copyright © 2025 Thasso | Powered by Responsive Theme